Goldman Sachs lifts target for Moderna stock to USD 137.00

Published on 10/26/2026 at 16:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna's market value was USD 79.2 billion on October 26, 2026. Moderna stock costs EUR 177.47 on October 26, 2026.

Goldman Sachs target rises

Goldman Sachs lifted its Moderna target from USD 120.00 to USD 137.00 on October 15, 2026.
The USD 137.00 target is 30.97 percent below Moderna's USD 198.47 Nasdaq price on October 26, 2026.
Moderna stock stood at EUR 177.47 at Lang & Schwarz on October 26, 2026 at 4:30 p.m. CET.
Moderna is scheduled to report third-quarter 2026 results on November 6, 2026.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Goldman Sachs lifted its Moderna target from USD 120.00 to USD 137.00 on October 15, 2026, while keeping a Neutral rating, MarketBeat reports. The revised target is 30.97 percent below Moderna's USD 198.47 Nasdaq price on October 26, 2026 at 11:33 a.m. EDT. At Lang & Schwarz, Moderna was trading at EUR 177.47 on October 26, 2026 at 4:30 p.m. CET.

Analyst targets remain below the quote

The Goldman Sachs revision is the latest visible target change in a broader analyst picture. MarketBeat lists 25 ratings, with 14 Holds, seven Buys and four Sells, alongside a consensus target of USD 103.95, as of October 25, 2026.

That spread puts the USD 137.00 target 30.97 percent below the Nasdaq quote, while the consensus target is 47.61 percent lower than USD 198.47. The figures frame Moderna as a stock whose market valuation has moved well ahead of the central analyst estimate.

Range and market value

Moderna's market capitalization was USD 79.2 billion on October 26, 2026. The Nasdaq-listed stock had a 52-week range of USD 22.28 to USD 254.48, with 10,541,305 shares traded in the latest quote.

The range shows a wide valuation envelope: the Nasdaq price was USD 56.01 below the 52-week high and USD 176.19 above the low on October 26, 2026. Moderna's negative P/E of 24.85 also reflects a loss-making earnings profile in the market snapshot.

Next results date is November 6

Moderna is scheduled to report its third-quarter 2026 results before the market opens on November 6, 2026, according to Simply Wall St. The report will give investors a new test of revenue trends and the company's continued investment in its messenger RNA pipeline.

Moderna price stays central

The current euro quote places Moderna below its annual Nasdaq high in original-currency terms, while the USD 137.00 Goldman Sachs target remains materially below the US market price. The next scheduled results date adds a fixed point for reassessing those valuation gaps.

The further course of trading is shown by the continuously updated real-time quote of Moderna stock.